Clinical trial
Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced…
NCT00483405 · UNC Lineberger Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00483405 |
|---|---|
| Title | Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer |
| Official title | Phase II Study of Oxaliplatin, Capecitabine, and Cetuximab in Advanced Hepatocellular Carcinoma |
| Acronym | NRR |
| Lead sponsor | UNC Lineberger Comprehensive Cancer Center, Other |
| Collaborators | Sanofi Industry Roche Pharma AG Bristol-Myers Squibb National Center for Research Resources (NCRR) NIH National Cancer Institute (NCI) |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Liver Cancer |
| Intervention type | Biological, Drug |
| Interventions | cetuximab, capecitabine, oxaliplatin |
| Enrollment | 33 |
| Start date | Oct 1, 2006 |
| Primary completion | Feb 1, 2010 |
| Completion | Dec 1, 2010 |
| First posted | Jun 7, 2007 |
| Last update posted | Jul 12, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: